Market Research Logo

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 5, 24 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development
A1M Pharma AB
Alloksys Life Sciences BV
Am-Pharma BV
Angion Biomedica Corp
Arch Biopartners Inc
Atox Bio Ltd
Balmes Transplantation SAS
Cellmid Ltd
CFM Pharma Holding BV
Cypralis Ltd
DURECT Corp
Evotec AG
Exponential Biotherapies Inc
F. Hoffmann-La Roche Ltd
GeneScience Pharmaceuticals Co Ltd
Klotho Therapeutics Inc
Kringle Pharma Inc
Mitobridge Inc
Mitotech SA
Quark Pharmaceuticals Inc
SBI Pharmaceuticals Co Ltd
Silver Creek Pharmaceuticals Inc
Spherium Biomed SL
STATegics Inc
Torrent Pharmaceuticals Ltd
Xigen SA
Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-4102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimapitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-0302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-0303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-0401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-4066 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerium oxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cilastatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Kidney Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUR-928 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EA-230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IL-233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iron sucrose + Sn protoporphyrin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-1052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-0204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metablok - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTB-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Plastomitin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPI-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-190 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Alkaline Phosphatase Enzyme Replacement for Acute Kidney Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Klotho Replacement for Kidney Disease, Aging, Breast Cancer, Cognitive Impairment and Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides to Agonize renalase for Acute Pancreatitis, Acute Kidney Injury and Cisplatin Induced Kidney Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize GHR for Growth Failure In Children With Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reltecimod sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RLS-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RMC-035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGF-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PADI4 for Acute Kidney Injury, Hepatic and Pancreatic Injuries - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GGT for Acute Renal Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Diabetic Foot Ulcers, Epidermolysis Bullosa, Liver Diseases, Kidney Disease, Peripheral Artery Occlusive Disease and Skin Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STSE-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUL-138 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRC-160334 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vanadis-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products
Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones
Featured News & Press Releases
Jul 09, 2018: Quark Pharmaceuticals Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
May 29, 2018: Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)
May 22, 2018: Arch Biopartners Engages Nucro-Technics To Complete Toxicology Studies To Support Investigational New Drug Application For Metablok
May 08, 2018: Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery Patients
Mar 21, 2018: Arch Biopartners Granted Pre-Ind Meeting With FDA for Candidate Drug to Prevent Acute Kidney Injury
Mar 09, 2018: AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
Feb 27, 2018: Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio
Nov 14, 2017: A1M Pharma reports positive results from its GLP toxicology study - now able to finalize application to initiate clinical studies
Nov 07, 2017: Quark Pharmaceuticals to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference
Nov 07, 2017: ROSgard protects bone marrow during radiation treatment - patent application has been filed
Nov 06, 2017: Mitobridge Presents Preclinical Data Demonstrating Beneficial Effects of PPARd Modulators in Acute Kidney Injury at American Society of Nephrology Annual Meeting
Nov 04, 2017: Quark Pharmaceuticals Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting
Nov 01, 2017: Quark Pharmaceuticals Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting
Oct 27, 2017: A1M Pharma: First company in the world with large scale manufacturing of A1M under full GMP compliance for clinical studies
Sep 13, 2017: Patented the first drug that acts as a protector of the kidney
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma BV, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Arch Biopartners Inc, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Ltd, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Balmes Transplantation SAS, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Ltd, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by CFM Pharma Holding BV, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cypralis Ltd, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corp, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Evotec AG, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Exponential Biotherapies Inc, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Klotho Therapeutics Inc, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma Inc, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitobridge Inc, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitotech SA, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals Inc, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Silver Creek Pharmaceuticals Inc, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed SL, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics Inc, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Ltd, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Xigen SA, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report